Company / Gross Profit
TherapeuticsMD, Inc. Gross Profit History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$68.6M
FY2023
5-year range
$1.2M / $68.6M
FY2019-FY2023
Trend
+5755.3%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit changed +5755% YoY in FY2023, a notable deviation from the 8-year average annual change of +746%.
Based on SEC 10-K filings.
$69M in FY2023 with a 5-year CAGR of +35.2%.
Improved from $43M to $69M over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +72.5%
- 5-Year CAGR
- +35.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +35.2%, indicating consistent growth.
- In FY2023, gross profit increased 5755.3% year-over-year.
- Lowest gross profit in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | $68.6M | +5755.3% |
| FY2022 | $1.2M | -97.3% |
| FY2021 | $43.3M | +224.1% |
| FY2020 | $13.4M | -5.5% |
| FY2019 | $14.1M | -6.8% |
| FY2018 | $15.2M | -3.0% |
| FY2017 | $15.6M | +37.7% |
| FY2016 | $11.4M | +66.6% |
| FY2015 | $6.8M | +176.0% |
As of FY2023 · SEC 10-K · Updated Jun 28, 2026